Participating Companies


Affimed N.V. [AFMD] US$227 MM MCap
NK cell en­gager AFM13 (CD30/CD16A) that is poised to en­ter a Phase 2 reg­is­tra­tion study in CD30-pos­i­tive pe­ripher­al T cell lym­pho­ma and an in­vesti­ga­tor-spon­sored study by MDACC of AFM13 com­bined with al­lo­gene­ic NK cells in re­lapsed/re­frac­to­ry CD30-pos­i­tive lym­pho­ma. Af­fimed al­so plans to file an IND in the third quar­ter of 2019 for AFM24, the com­pany’s in­nate cell en­gager that tar­gets EGFR-ex­press­ing solid tu­mors. [more in­for­ma­tion]
Amarin Corporation [AMRN] US$6,051 MM MCap
Vas­ce­pa: 1st and on­ly pure EPA ome­ga-3 fat­ty acid ap­proved to low­er trig­lyc­eride lev­els in adults. Pre­sent­ed (+) da­ta from RE­DUCE-IT CV Out­comes trial at AHA [more in­for­ma­tion]
Apexigen
CD40 ag­on­ist mAb; 170+ pts dosed (mono & com­bi sett­ings). 7 on­go­ing Ph 2s, undis­closed oc­u­lar dis­ease pro­gram in Ph 3. AACR: Ph 1b da­ta (w/Park­er Inst); col­labs w/BMY, MDACC, Yale, et al [more in­for­ma­tion]
Arcellx
Cur­rent en­gi­neered im­mune cell ther­a­pies of­ten tar­get tu­mors through a mono-spe­cif­ic re­cep­tor that is con­sti­tu­tive­ly ex­pressed and ac­tive. In con­trast, Ar­cel­lx has de­vel­oped Anti­gen Re­cep­tor Com­plex T cells (ARC-T) that are read­i­ly si­lenced, ac­ti­vat­ed, and re­pro­grammed in vi­vo by ad­min­is­tra­tion of a tu­mor-tar­get­ing anti­gen pro­tein called a sparX. [more in­for­ma­tion]
AsclepiX Therapeutics
AX­T107 de­mon­s­trat­ed ef­fi­ca­cy and dura­bil­i­ty in rab­bit and mouse mod­els that is su­pe­ri­or to stan­dard of care Eye­lea. [more in­for­ma­tion]
Asklepion Pharmaceuticals
Pri­vate, fo­cused on the de­vel­op­ment of IV Cit­rul­line for rare pe­di­a­tric dis­eas­es. First in­di­ca­tion, the pre­ven­tion of sig­ni­f­i­cant se­que­lae of pe­di­a­tric acute car­diopul­mo­nary by­pass-in­duced lung in­jury, Ph 3 trial is on­go­ing. [more in­for­ma­tion]
Assembly Biosciences, Inc. [ASMB] US$381 MM MCap
The mi­cro­biome pro­gram is de­vel­op­ing nov­el oral live mi­cro­bial bio­ther­a­peu­tic can­di­dates with As­sem­b­ly’s ful­ly in­te­grat­ed plat­form, in­clud­ing a ro­bust pro­cess for strain iden­ti­fi­ca­tion and se­lec­tion, GMP bank­ing and pro­duc­tion, and tar­get­ed de­liv­ery to the low­er gas­troin­testi­nal tract with the GEMI­CEL® tech­nol­o­gy. [more in­for­ma­tion]
Bellus Health [BLU:CA] Can$535 MM MCap
BEL­LUS' lead prod­uct can­di­date, BLU-5937, is be­ing de­vel­oped for the treat­ment of chron­ic cough (Phase II an­nounced Ju­ly 2020) and chron­ic pru­ri­tus (Phase II planned to be­gin 1H20). [more in­for­ma­tion]
Biohaven Pharmaceuticals, Inc [BHVN] US$2,487 MM MCap
Pre­sent­ed ex­pand­ed da­ta at AHS (Ju­ly 2019) /dosed 1,780+ pa­tients (com­bined ex­po­sure of 105k dos­es) and ex­pand­ed safe­ty & pre­lim pre­ven­tive ef­fi­ca­cy da­ta (May 2019) from long-term safe­ty study. Up­com­ing mile­s­tones: Ph 3 to­p­line da­ta in pre­ven­tive treat­ment of mi­graine (rimege­pant) & Ph 2/3 to­p­line ef­fi­ca­cy & safe­ty in in­tra­nasal (BHV-3500) for acute treat­ment of mi­graine in 4Q19. [more in­for­ma­tion]
BrainStorm Cell Therapeutics Inc. [BCLI] US$91 MM MCap
NurOwn® au­tol­o­gous cell ther­a­py plat­form for neu­rode­gen­er­a­tive dis­eas­es. Lead can­di­date for ALS, Ph2 eval­u­at­ed 60 ALS pts w fa­vor­able safe­ty/tol­er­a­bil­i­ty. Ph3 cur­rent­ly en­rolling 200 pts across 6 US cen­ters; top-line da­ta ex­pect­ed in mid-2020. Phase 2 trial in pro­gres­sive MS on­go­ing at Cleve­land Clin­ic and Stan­ford Uni­ver­si­ty - to­p­line da­ta mid-2020. [more in­for­ma­tion]
CASI Pharmaceuticals Inc. [CASI] US$311 MM MCap
NM­PA re­view in progress for ZE­VALIN® and MAR­QI­BO® (in-li­censed from Spec­trum). Re­cent­ly (2Q19) acq'd ex­clu­sive WW rights to com­mer­cial­ize an­ti-CD19 T-cell ther­a­py (CNC­T19) in Chi­na as well as ex­clu­sive WW rights to nov­el an­ti-CD38 mAb (CID-103). Acq'd 25 US FDA-ap­proved AN­DAS from San­doz in Jan 2018. [more in­for­ma­tion]
Cellular Biomedicine Group, Inc. [CBMG] US$287 MM MCap
Vali­dates CB­MG's in-house cell man­u­fac­tur­ing ca­pa­bil­i­ties de­vel­oped in part­n­er­ship with Gen­er­al Elec­tric and Ther­mo Fish­er. CB­MG's pro­pri­e­tary im­muno-on­col­o­gy pipe­line in­cludes BC­MA, CD22, TCR-T for HCC and TIL for the treat­ment of NS­CLC and other solid tu­mors. [more in­for­ma­tion]
Genfit SA [GNFTF] US$653 MM MCap
$155m Mar 2019 US IPO; FDA BTD for Ela­fi­branor (4/19); (+) 36-mo DSMB rec for cont­in­u­a­tion of Ph 3 study in NASH; da­ta by YE [more in­for­ma­tion]
Hutchison China MediTech Ltd ("Chi-Med") [HCM] US$2,696 MM MCap
Chi-Med has a port­fo­lio of 9 drugs in clin­i­cal de­vel­op­ment from own dis­cov­ery en­gine in its In­no­va­tion plat­form and a cash gen­er­at­ing Com­mer­cial plat­form with 2,500+ sales reps. Glob­al col­lab­o­ra­tion with As­traZene­ca in two reg­is­tra­tion en­abling studies with savol­i­tinib in Ta­gris­so re­frac­to­ry lung can­cer that is MET+ and EGFRm+ (glob­al) and MET Ex­on 14 dele­tion NS­CLC (Chi­na). [more in­for­ma­tion]
Immatics Biotechnologies GmbH
Im­mat­ics is build­ing a broad pro­pri­e­tary and part­nered pipe­line of au­tol­o­gous (AC­Tolog, ACTengine), al­lo­gene­ic (AC­Tal­lo) and Bis­pe­cif­ic TCR ap­proach­es, with 4 on­go­ing Phase 1/2 trials in col­lab­o­ra­tion with MD An­der­son Can­cer Cen­ter. [more in­for­ma­tion]
Kadmon Holdings, Inc. [KDMN] US$350 MM MCap
Plat­form of ROCK in­hibi­tors. ROCK2 in­hibi­tor in reg­is­tra­tion trial cGVHD; en­roll­ment com­ple­tion exp 2H19; ini­tial anal­y­sis exp YE. Ph 2 ini­ti­a­tion in scle­ro­der­ma exp in 2019. [more in­for­ma­tion]
Kineta Inc.
Kine­ta (Pri­vate) is fo­cused on in­nate im­mu­ni­ty and im­munol­o­gy. Signed 2 large ear­ly stage part­ner­ing deals in 2018 - $520M deal with Pfiz­er for its small molecule RIG-I im­munother­a­py and a $360M+ deal with Ge­nen­tech for KCP506, a pre­clin­i­cal, non-opi­oid for chron­ic pain. LHF-535 in Ph 1 for Las­sa Fev­er (fund­ed by Well­come Trust, eli­gi­ble for PRV). [more in­for­ma­tion]
Lineage Cell Therapeutics [LCTX] US$157 MM MCap
Cur­rent­ly has 3 clin­i­cal pro­grams: (i) OpRe­gen®, a reti­nal pig­ment epithe­li­um tran­s­plant ther­a­py in Ph 1/2a de­vel­op­ment for dry AMD; ii) OPC1, an oli­go­den­dro­cyte pro­gen­i­tor cell ther­a­py in Ph 1/2a de­vel­op­ment for acute spi­nal cord in­juries; and (iii) VAC2, an al­lo­gene­ic can­cer im­munother­a­py of anti­gen-pre­sent­ing den­drit­ic cells cur­rent­ly in Ph 1 for NS­CLC. [more in­for­ma­tion]
Nanobiotix SA [NANO:PA] €195 MM MCap
Nano­bi­otix is a lead­ing, clin­i­cal-stage nanomedicine com­pany pi­oneer­ing new ap­proach­es to sig­ni­f­i­cant­ly change pa­tient out­comes by bring­ing nano­physics to the heart of the cell. Nano­bi­otix’s Im­muno-On­col­o­gy pro­gram has the po­ten­tial to bring a new di­men­sion to can­cer im­munother­a­pies. [more in­for­ma­tion]
Neoleukin Therapeutics [NLTX] US$94 MM MCap
Re­cent­ly went public through merg­er with Aqui­nox. De­sign­ing de no­vo pro­tein im­munother­a­pies us­ing com­pu­ta­tio­n­al meth­ods. Lead pro­gram NEO-201: cy­tokine mimet­ic (ne­oleukin) to ac­ti­vate im­mune cells for can­cer; first de no­vo pro­tein ther­a­peu­tic ev­er cre­at­ed. [more in­for­ma­tion]
NeuroRx
The Com­pany re­port­ed Phase 2 ef­fi­ca­cy and safe­ty da­ta for NRX-011 in De­cem­ber 2018, suggest­ing po­ten­tial for NRX-101 in main­tain­ing re­mis­sion from sev­er­al bipo­lar de­pres­sion with acute sui­ci­dal idea­tion fol­low­ing an ini­tial sta­bi­l­iza­tion with ke­tamine. [more in­for­ma­tion]
PAION AG [PAIOF] US$162 MM MCap
Remi­ma­zo­lam: short-act­ing anes­thet­ic. Ph 3 study in pro­ce­du­ral se­da­tion in US. Safe­ty da­ta in ASA III/IV pa­tients in Ph 3 colonos­copy study and Ph 3 bron­chos­copy study. US ap­pro­val filed by part­n­er Cos­mo Phar­ma­ceu­ti­cals in June 2019. Ini­ti­at­ed Ph 3 in gen­er­al anes­th­e­sia in EU in Ju­ly 2018, exp com­ple­tion 2019. [more in­for­ma­tion]
Pharming Group NV [PHARM:AS] €817 MM MCap
On­ly prod­uct with fu­ture po­ten­tial to be ap­proved for both pro­phy­laxis and treat­ment of at­tacks of HAE. An­nounced pos­i­tive re­sults from a ph2 study of RU­CON­EST in Con­tract-in­duced Nephro­pa­thy for pa­tients re­ceiv­ing elec­tive coro­nary an­giog­ra­phy with or with­out a per­cu­ta­neous coro­nary in­ter­ven­tion (PCI). [more in­for­ma­tion]
Pharvaris
Phar­varis is fo­cused on bring­ing an oral bradykinin B2 re­cep­tor an­ta­g­on­ist to pa­tients for use as an al­ter­na­tive to in­ject­ed ther­a­pies for hered­i­tary an­gioede­ma (HAE) and other B2 re­cep­tor-me­di­at­ed in­di­ca­tions. POC was de­mon­s­trat­ed in a mon­key mod­el and it’s ap­pli­ca­ble to all pa­tients in HAE. [more in­for­ma­tion]
Pieris Pharmaceuticals, Inc. [PIRS] US$261 MM MCap
An­ti­calins (en­gi­neered lipo­calin pro­teins) for re­sp & on­co dis­eas­es. Im­mi­nent da­ta for AZN-part­nered PRS-060 in­haled IL4 for mod-to-se­vere asth­ma. Cash of $128MM in the bank as of March 2019. [more in­for­ma­tion]
Pliant Therapeutics, Inc.
Pliant has de­vel­oped a port­fo­lio of ful­ly-owned de­vel­op­ment can­di­dates fo­cused on in­hibit­ing the TGFb path­way through in­te­grin in­hi­bi­tion. The com­pany’s lead prod­uct can­di­date, PLN-74809 is an oral small-molecule du­al se­lec­tive in­hibi­tor of &al­pha;vß6 and &al­pha;vß1 in­te­grins that is be­ing de­vel­oped in idio­path­ic pul­mo­nary fi­bro­sis (IPF), and pri­mary scle­ros­ing cholan­gi­tis (PSC). [more in­for­ma­tion]
Protagonist Therapeutics [PTGX] US$364 MM MCap
PN-943 oral GI-re­strict­ed al­pha-4-be­ta-7 an­ta­g­on­ist Ph 2 in ul­cer­a­tive coli­tis to be­gin in ear­ly 2020; and PTG-200, part­nered w/ Janssen, oral GI-re­strict­ed IL-23R an­ta­g­on­ist to be­gin Ph 2 Crohn’s dis­ease study in 4Q19. [more in­for­ma­tion]
Quentis Therapeutics
Lead pro­gram is a first-in-class IRE1&al­pha; in­hibi­tor de­signed to boost an­ti-tu­mor im­mu­ni­ty in can­cer. Quen­tis is pur­su­ing ther­a­pies to ad­dress mul­ti­ple ER stress path­way tar­gets in the tu­mor mi­cro-en­vi­ron­ment, as well as in other dis­eas­es where ER stress plays an im­por­tant role. Quen­tis launched in Fe­bruary 2018 with a $48 mil­lion Se­ries A fi­nanc­ing. [more in­for­ma­tion]
Strongbridge Biopharma [SBBP] US$148 MM MCap
Rare dis­eas­es; Keveyis for PPP 2019 rev­enue gui­dance of $18-20M; Re­cor­lev 2nd Phase 3 top-line re­sults 1Q 2020; NDA sub­mis­sion exp 3Q 2020 [more in­for­ma­tion]
Targovax [TRVX:OS] NKr333 MM MCap
On­co­lyt­ic ade­n­ovirus armed w im­mune sti­m­u­lat­ing trans­gene tar­get­ing bas­ket of I-O in­di­ca­tions. Strong re­sults from Part 1 (ON­COS-102/Keytru­da com­bo) trial in an­ti-PD1 re­frac­to­ry me­lano­ma: 33% ORR in 9 pts: 1 CR, 2 PRs; im­mune ac­ti­va­tion de­mon­s­trat­ed in all 9 pts. Jan 2020: exp ran­domized da­ta, Ph 1b/ 2 (me­sothe­lio­ma, n=31) w/che­mo [more in­for­ma­tion]
vTv Therapeutics, Inc. [VTVT] US$90 MM MCap
June 2019 pos­i­tive da­ta for TT­P399 as an add-on ther­a­py to in­sulin ther­a­py in a 12 week phase 1/2 trial in pa­tients with T1D. Re­cent­ly an­nounced the first pa­tient has been screened for the Ph2 proof of con­cept study eval­u­at­ing the safe­ty and ef­fi­ca­cy of azeli­ra­gon in pa­tients with mild Alzheimer's dis­ease and Type 2 Di­a­betes. [more in­for­ma­tion]
Yisheng Biopharma
Prod­ucts in de­vt in­clude YS-ON-001 (Ph 1), an IO prod­uct tar­get­ing solid tu­mors and new gen of bi­o­log­ics for pre­ven­tive and ther­a­peu­tic ben­e­fits, in­cl YS-HBV-001 (Ph 1) and PI­KA ra­bies vaccine (Ph 3), tar­get­ing hep B and ra­bies in­fec­tions. GMP cer­ti­fi­ca­tion re­ceived Ju­ly 2019 for Ju­nan, the first med­i­cal freeze-dried ra­bies vaccine with­out an alu­minum ad­ju­vant pro­duced in Chi­na. [more in­for­ma­tion]